Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medplus Health Services' subsidiary Optival Health Solutions received two drug license suspension orders from state drug control authorities. A store in Malavalli Mysore Road, Karnataka faces a 5-day suspension, while a store in Psr Center Suryapet, Telangana faces a 3-day suspension. Both actions were taken under Rule 65 of the Drugs and Cosmetics Act, 1940. The combined potential revenue loss from these suspensions is approximately Rs 1.97 lakhs (Rs 0.96 lakhs for the Karnataka store and Rs 1.01 lakhs for the Telangana store). The orders were received on September 27, 2025, and the company disclosed this to the stock exchanges on September 28, 2025.
The financial impact is negligible — combined potential revenue loss of under Rs 2 lakhs is immaterial to Medplus's overall operations given its large store network. Shareholders are unlikely to see any meaningful impact on the stock price from this routine regulatory action.